Carteolol HCl Ophthalmic Solution Rx
Generic Name and Formulations:
Carteolol HCl 1%; contains benzalkonium chloride.
Indications for Carteolol HCl Ophthalmic Solution:
Open-angle glaucoma. Ocular hypertension.
1 drop in affected eye(s) twice daily. Concomitant pilocarpine and other miotics, and/or epinephrine or dipivefrin, and/or systemically administered carbonic anhydrase inhibitors may be used if needed.
Sinus bradycardia. Greater than 1st-degree AV block. Cardiogenic shock. Overt cardiac failure. Asthma. Severe COPD.
History of cardiac failure or heart block. Discontinue at 1st sign of cardiac failure. Pulmonary impairment. Diabetes (esp. labile). May mask hypoglycemia and hyperthyroidism. May potentiate muscle weakness. Discontinue before general anesthesia. Avoid abrupt cessation. Pregnancy (Cat.C). Nursing mothers.
May potentiate or be potentiated by systemic β-blockers. May potentiate reserpine, hypoglycemics. May antagonize adrenergic psychotropics.
Ocular: transient eye irritation, burning, tearing, conjunctival hyperemia and edema, blurred/cloudy vision, photophobia, decreased night vision, ptosis; rarely: blepharoconjunctivitis, abnormal corneal staining, corneal sensitivity. Systemic: cardiac arrhythmia, heart palpitation, dyspnea, asthenia, headache, dizziness, insomnia, sinusitis, taste perversion.
Formerly known under the brand name Ocupress.
Soln—5mL, 10mL, 15mL
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- Finding Clinical Trials in Cancer
- Combining Chemotherapy With Checkpoint Inhibitors Extends Overall Survival in ES-SCLC
- In a Head-to-Head Battle, Brigatinib Appears to Best Crizotinib
- Durvalumab Shows Overall Survival Benefit in Patients With Stage III NSCLC
- Baseline Thrombopoietin Levels May Help Predict Response to ITP Treatment
- Despite Promising Trial Results, Skeptics Raise Red Flags About Anlotinib's Efficacy in Heavily Treated NSCLC